Drug Trial Radar · NCT00591422
Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Aug 2007
Primary completion
Mar 10, 2010
Study completion Mar 10, 2011
Sponsor
- Lead sponsor
- Alaunos TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 11, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study of Dariniparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Conditions
- Advanced Cancer
Interventions
ZIO-101-C (Darinaparsin)Drug
Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (\>36 hours between doses) for 3 weeks with 1 week rest.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ToxicitiesTime frame: 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Ocoee, Florida
Site not named
Dallas, Texas
Site not named
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.